Format
Items per page
Sort by

Send to:

Choose Destination

Results: 18

Related Articles by Review for PubMed (Select 18493310)

1.

Efficacious recombinant influenza vaccines produced by high yield bacterial expression: a solution to global pandemic and seasonal needs.

Song L, Nakaar V, Kavita U, Price A, Huleatt J, Tang J, Jacobs A, Liu G, Huang Y, Desai P, Maksymiuk G, Takahashi V, Umlauf S, Reiserova L, Bell R, Li H, Zhang Y, McDonald WF, Powell TJ, Tussey L.

PLoS One. 2008 May 21;3(5):e2257. doi: 10.1371/journal.pone.0002257.

2.

Synthetic recombinant vaccines against viral agents.

Arnon A, Levi R.

Int Arch Allergy Immunol. 1995 Dec;108(4):321-6. Review.

PMID:
7580302
3.

Universal M2 ectodomain-based influenza A vaccines: preclinical and clinical developments.

Schotsaert M, De Filette M, Fiers W, Saelens X.

Expert Rev Vaccines. 2009 Apr;8(4):499-508. doi: 10.1586/erv.09.6. Review.

4.

Emulsion-based adjuvants for influenza vaccines.

Vogel FR, Caillet C, Kusters IC, Haensler J.

Expert Rev Vaccines. 2009 Apr;8(4):483-92. doi: 10.1586/erv.09.5. Review.

PMID:
19348563
5.

Recombinant proteins produced in insect cells.

Treanor J.

Curr Top Microbiol Immunol. 2009;333:211-25. doi: 10.1007/978-3-540-92165-3_11. Review.

PMID:
19768408
7.

Candidate influenza vaccines based on recombinant modified vaccinia virus Ankara.

Rimmelzwaan GF, Sutter G.

Expert Rev Vaccines. 2009 Apr;8(4):447-54. doi: 10.1586/erv.09.4. Review.

PMID:
19348560
8.

Towards an epitope-based human vaccine for influenza.

Ben-Yedidia T, Arnon R.

Hum Vaccin. 2005 May-Jun;1(3):95-101. Epub 2005 May 15. Review.

9.

Prospects for an influenza vaccine that induces cross-protective cytotoxic T lymphocytes.

Brown LE, Kelso A.

Immunol Cell Biol. 2009 May-Jun;87(4):300-8. doi: 10.1038/icb.2009.16. Epub 2009 Mar 24. Review.

PMID:
19308073
10.

Soluble recombinant influenza vaccines.

Fiers W, Neirynck S, Deroo T, Saelens X, Jou WM.

Philos Trans R Soc Lond B Biol Sci. 2001 Dec 29;356(1416):1961-3. Review.

11.

Pandemic influenza vaccines.

DiMenna LJ, Ertl HC.

Curr Top Microbiol Immunol. 2009;333:291-321. doi: 10.1007/978-3-540-92165-3_15. Review.

PMID:
19768412
12.

[Using reverse genetics method for developing recombinant strains of influenza viruses acceptable for use as live attenuated vaccines].

Merkulov VA, Lebedev VN, Plekhanova TM, Maksimov VA, Korovkin SA, Mironov AN.

Zh Mikrobiol Epidemiol Immunobiol. 2009 Mar-Apr;(2):111-7. Review. Russian.

PMID:
19462520
13.

Pandemic preparedness: toward a universal influenza vaccine.

Roose K, Fiers W, Saelens X.

Drug News Perspect. 2009 Mar;22(2):80-92. doi: 10.1358/dnp.2009.22.2.1334451. Review.

PMID:
19330167
14.

Using plant cells as influenza vaccine substrates.

Chichester JA, Haaheim LR, Yusibov V.

Expert Rev Vaccines. 2009 Apr;8(4):493-8. doi: 10.1586/erv.09.3. Review.

PMID:
19348564
15.

Influenza virus-like particles as pandemic vaccines.

Kang SM, Pushko P, Bright RA, Smith G, Compans RW.

Curr Top Microbiol Immunol. 2009;333:269-89. doi: 10.1007/978-3-540-92165-3_14. Review.

PMID:
19768411
16.

Attenuated influenza A viruses with modified cleavage sites in hemagglutinin as live vaccines.

Stech J.

Expert Rev Vaccines. 2008 Aug;7(6):739-43. doi: 10.1586/14760584.7.6.739. Review.

PMID:
18665773
17.

Prospects for developing an effective particle-mediated DNA vaccine against influenza.

Yager EJ, Dean HJ, Fuller DH.

Expert Rev Vaccines. 2009 Sep;8(9):1205-20. doi: 10.1586/erv.09.82. Review.

PMID:
19722894
18.

[Advances in the study of influence vaccines].

An NL, Zhang ZQ.

Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 1998 Dec;12(4):398-400. Review. Chinese. No abstract available.

PMID:
12526362
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk